Blocking a single signaling pathway in aged mice carrying APOE4 restored pericyte coverage of brain blood vessels and cut both vascular fibrosis and amyloid accumulation — the central result of a study published in Cell by researchers at the Icahn School of Medicine at Mount Sinai. The finding positions APOE4-driven cerebrovascular degeneration, long treated as a passive endpoint of Alzheimer's disease, as a therapeutically tractable process.

The paper, "A pericyte-to-myofibroblast transition links APOE4 to cerebrovascular degeneration," appears alongside a companion study in Cell Stem Cell, "Cholesterol dysregulation in APOE4 astrocytes promotes α-synuclein pathology in miBrains." Both come from Mount Sinai labs and both address the same portfolio-level question: by what mechanism does APOE4, the strongest common genetic risk factor for Alzheimer's, damage brain tissue — and which steps can a drug actually hit?

A transcriptomic atlas of the vasculature

The Cell study began with data integration rather than new sequencing. The team combined existing datasets into a single-cell transcriptomic atlas of the human brain's vasculature, producing a map of gene activity across the cells that build and support blood vessels. Interrogating that map, they found that APOE4 pushes pericytes — the cells that stabilize small vessels and maintain the blood-brain barrier — to transform into scar-forming, myofibroblast-like cells. The transition drives vascular fibrosis and increases amyloid deposition around vessels, conditions the authors link to compromised blood flow and neurodegeneration.

The interventional leg of the study used aged APOE4 mice. Blocking TGF-β signaling, a pathway involved in cellular communication and tissue remodeling, restored pericyte coverage and reduced fibrosis and vascular amyloid. In effect, the researchers demonstrated reversal, not merely slowing, of APOE4-associated cerebrovascular degeneration in the model.

"Damage to the brain's blood vessels is not simply a late consequence of Alzheimer's disease; it is a biologically active process caused by APOE4 that may be reversible," said Joel Blanchard, PhD, associate professor of neuroscience, and stem cell biology and regenerative medicine at Mount Sinai and a corresponding author on the study.

First author Braxton Schuldt, an MD/PhD candidate in neuroscience in the Blanchard Laboratory, added: "Through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain's circulation in people at high genetic risk for Alzheimer's disease."

Two caveats bear on any translational readout. The pericyte findings come from an atlas built on existing human datasets plus aged-mouse intervention data, not from a human trial; the TGF-β result establishes tractability in the model but says nothing yet about dosing, safety or efficacy in patients. TGF-β signaling also acts broadly across tissues, so pathway-level blockade carries off-target exposure that a program would need to manage.

Cholesterol, lysosomes and α-synuclein in 3D tissue

The Cell Stem Cell study shifts the target from vessels to protein aggregation. The Mount Sinai team and external collaborators used miBrains — three-dimensional human brain tissues derived from induced pluripotent stem cells and developed in-house — to model how APOE4 promotes the abnormal protein buildup seen in Alzheimer's and Parkinson's. The tissues contain neurons, glial cells, myelin-producing cells and vessel-forming cells, and they reproduce the APOE4 phenotype: miBrains carrying the variant accumulate higher levels of abnormal alpha-synuclein, the protein associated with Lewy body dementia and Parkinson's disease.

Mechanistically, the experiments showed that APOE4 causes cholesterol to accumulate in astrocytes. The excess cholesterol impairs the astrocytes' lysosomal waste-disposal system, reducing their capacity to degrade alpha-synuclein. The protein instead aggregates and spreads to neurons, forming harmful deposits. The study identifies astrocyte cholesterol metabolism and lysosomal function as candidate therapeutic targets spanning both Alzheimer's and Parkinson's — a two-indication claim that broadens the commercial relevance of the pathway, if it replicates.

The platform itself carries methodological weight for R&D groups. "A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved," said Louise Mesentier-Louro, PhD, assistant professor of neuroscience, and stem cell biology and regenerative medicine at Mount Sinai and first author of the study. "This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation."

Cryopreservation of defined-composition organoids addresses a chronic bottleneck in 3D tissue work — batch-to-batch variability — and the claim of predefined cellular composition distinguishes miBrains from less controlled differentiation protocols. As with any iPSC-derived model, how faithfully the tissues recapitulate aged human brain vasculature remains the gating question for external validation.

For portfolio planners, the two papers converge on a single thesis: APOE4's damage runs through specific, measurable cell-state transitions — pericyte-to-myofibroblast scarring and astrocyte cholesterol-lysosome failure — each with an identifiable intervention point. The Mount Sinai group has not announced a clinical program, but the TGF-β blockade and cholesterol-metabolism targets now enter preclinical contention for Alzheimer's programs focused on the high-risk APOE4 population.